Dharti Proteins Ltd receives BSE approval to trade 5,00,000 equity shares effective October 8, 2026. This follows the successful implementation of an NCLT-approved resolution plan, which included a major capital reduction and change in control.
Dharti Proteins Resumes Trading on BSE
5,00,000 equity shares admitted to trading; previous paid-up capital of Rs 10.27 crore reduced to Rs 50 lakh.
Reader Takeaway: Resolution plan marks a fresh start under new management; trade-to-trade status persists, signaling continued regulatory caution.
What just happened
BSE has granted trading approval for 5,00,000 equity shares of Dharti Proteins Ltd (formerly Devika Proteins Ltd) effective October 8, 2026. This development follows an NCLT Ahmedabad Bench order dated November 18, 2025, which mandated the restructuring of the company under the Insolvency and Bankruptcy Code.
Why this matters
The resumption of trading marks the formal end of the insolvency process and the transition to a new promoter group. The capital restructuring involved the total extinguishment of shares held by erstwhile promoters and a significant reduction of existing paid-up shares from 1,02,77,200 to 5,00,000.
The Resolution Plan
The company’s equity structure now reflects the interests of the new stakeholders:
- 4,25,000 shares are held by the Successful Resolution Applicant (SRA).
- 50,000 shares are allocated to secured financial creditors.
- 25,000 shares remain with public shareholders on a proportionate basis.
Risks to watch
Shares will continue to be traded under the 'XT' group (Trade-to-Trade segment). Investors should note that 'XT' stocks often experience lower liquidity and higher volatility, requiring caution until operational stability is established under the new management team.
What to track next
Shareholders should monitor the company's first post-resolution quarterly performance updates and any strategic shifts in business operations as announced by the new SRA-led management.